| Literature DB >> 33483442 |
Zhuolin Qu1,2, Asma Azizi3, Norine Schmidt4, Megan Clare Craig-Kuhn4, Charles Stoecker5, James Mac Hyman1, Patricia J Kissinger6.
Abstract
OBJECTIVE: Chlamydia trachomatis (Ct) is the most commonly reported sexually transmitted infection in the USA and causes important reproductive morbidity in women. The Centers for Disease Control and Prevention recommend routine screening of sexually active women under age 25 but not among men. Despite three decades of screening women, chlamydia prevalence in women remains high. Untested and untreated men can serve as a reservoir of infection in women, and male-screening based intervention can be an effective strategy to reduce infection in women. We assessed the impact of screening men on the Ct prevalence in women.Entities:
Keywords: infection control; public health; statistics & research methods
Year: 2021 PMID: 33483442 PMCID: PMC7831743 DOI: 10.1136/bmjopen-2020-040789
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Summary of interventions involved in the Check It programme
| Intervention | Description |
| VBS | Venue-based screening by recruiting male participants at non-clinical community venues |
| EIT | Expedited index treatment by providing medication to the Ct-positive men |
| EPT | Expedited partner treatment by providing medication to partners of the index men without a medical examination |
| SNPR | Social network peer referral encourages men to refer young AA men in their social network to Check It to increase the total enrolment |
| Rescreening | Ct-positive men are retested for infection 3 months after treatment |
AA, African American; Ct, Chlamydia trachomatis.
Model parameters for the AA population aged 15–24
| Description | Baseline | Range for 95% Confidence Interval | Reference | |
| Transmissibility from men to women per contact | 0.30 | 0.04 to 0.5* | ||
| Transmissibility from women to men per contact | 0.10 | 0.04 to 0.25 | ||
| Average time to recovery without treatment (years) | 1.32 | exponential | ||
| Average time to recovery after treatment (days) | 7 | exponential | ||
| Fraction of condom use for primary partners | 0.54 | – | ||
| Fraction of condom use for casual partners | 0.66 | – | ||
| Condom failure rate | 0.1 | – | ||
| Fraction of symptomatic infections screened | 0.7 | 0.6 to 0.8 | ||
| Time lag in screening for symptomatic infection (days) | 21 | 14 to 28 | ||
| Intervention parameters among young AA women | ||||
| Fraction of the target women who are screened annually | 0.6 | 0.56 to 0.65 | ||
| Fraction of symptomatic infection in women | 0.3 | – | ||
| Fraction of partner treatment for index women | 0.24 | – | Derived | |
| - Fraction of physicians practicing partner treatment | 0.4 | 0.3 to 0.5 | ||
| - Fraction of compliance for partner treatment | 0.6 | 0.4 to 0.8 | ||
| Fraction of treated women who are rescreened | 0.2 | 0.17 to 0.28 | ||
| Time lag in treatment for screened women (days) | 2 | – | ||
| Time lag in partner treatment for treated women (days) | 6 | 0 to 15 | ||
| Time lag in rescreening for treated women (days) | 105 | 80 to 130 | ||
| Intervention parameters among young AA men | ||||
| Fraction of target population enrolled per year | 0.075 | |||
| - Fraction of non-peer VBS-enrolment | 0.76 | |||
| - Fraction of SNPR enrolment | 0.24 | |||
| Number of peer-recruited men per VBS-enrolled man | 0.32 | Derived | ||
| Fraction of symptomatic Ct infection in men | 0.11 | |||
| Fraction of screened positive men treated (EIT) | 0.76 | 0.1 to 0.9 | ||
| Fraction of partner treatment for index men (EPT) | 0.27 | 0.1 to 0.9 | ||
| Fraction of treated men with rescreening | 0.12 | 0.1 to 0.9 | ||
| Time lag in treatment for screened men (days) | 12 | – | ||
| Time lag in screening for men enrolled via SNPR (days) | 7 | – | Assume | |
| Time lag in partner treatment for treated men (days) | 2 | – | ||
| Time lag in rescreening for treated men (days) | 102 | – |
*For the disease transmissibility parameters ( and ), the estimated ranges come from the mathematical modelling papers. In our study, we estimated the baseline values for these transmission rates by calibrating the model to the Ct prevalences in the AA population within the age range (10.2% in men and 13.5% in women).
AA, African American; Ct, Chlamydia trachomatis; EIT, expedited index treatment; EPT, expedited partner treatment; SNPR, social network peer referral; VBS, venue-based screening.
Figure 1Flowchart for Ct intervention strategies in men and women. The solid lines are the new practices incorporated in the male-screening programme, Check It, and the dashed lines are the existing interventions implemented in the healthcare system. These current interventions include women’s annual screening and screenings prompted by symptomatic infections in both men and women. Our modelling effort assessed the net impact of the male-screening programme to help control the Ct epidemic. The Check It programme targets the male population and uses venue-based enrolment, expedited index treatment, expedited partner treatment, rescreening and social network peer referral (see table 1). The intervention parameters are marked along the routes indicating the rates of compliance and delays, obtained from either literature or Check It data (see table 2). Ct,Chlamydia trachomatis.
Figure 2Impact of male-screening programme implemented at the existing intervention level. The curves are the mean of 50 stochastic simulations, and the bands around the curves indicate the one SD. The baseline Ct prevalences (before year 0) are 13.5% and 10.2% in women and men, respectively. At year 0, the male-screening intervention is turned on. Around year 5, the Ct prevalences reach quasi-steady states, which are 12.4% in women and 9.3% in men. The prevalences are reduced by 8.1% in women and 8.8% in men relatively. When the male-screening programme is stopped around year 14, the Ct prevalences return to the baseline levels in about 5.5 years. Ct,Chlamydia trachomatis.
Figure 4Local and extended sensitivity analysis on expedited partner treatment (on the x-axis) against the Ct prevalence (y-axis). Left: the analysis at the current level of Check It intervention intensity, screening 7.5% of the target male population. Together with the results in figure 3 and at the current Check It level, the significance of intervention components is ranked as venue-based screening expedited index treatment >expedited partner treatment >rescreening. Right: the analysis at a much higher 40% male-screening rate while fixing other intervention parameters. The magnitude of the local sensitivity index is almost seven times larger (-0.117 vs −0.017), which suggests that the partner treatment becomes more important in reducing prevalence when increasing the screening coverage in men. Ct,Chlamydia trachomatis; EIT, expedited index treatment.
Figure 3Local and extended sensitivity analysis on Check It intervention parameters (on the x-axis) against the Ct prevalence (y-axis). For each plot, the parameter of interest is varied while the other model parameters are fixed as in table 2. The Ct prevalences for men, women and the entire population are plotted, which are averaged over the time-frame year 4.5~5.5 of 30 simulations. The error bars give the one SD above and below the average. The local sensitivity indices (q=quantity of interest is Ct prevalence) are given in the titles. Ct,Chlamydia trachomatis; EIT, expedited index treatment; VBS, venue-based screening.
Figure 5Global sensitivity analysis of Ct prevalence in women (marked in contour lines) against two intervention parameters: venue-based screening (VBS, x-axis) and expedited partner treatment (EPT, y-axis) on a uniform 55 grid. At each grid point, the Ct prevalence is averaged over the time-frame year 4.5~5.5 of 10 simulations, and the contour surface is smoothed by a least-square fit of a two-dimensional quadratic polynomial to the grid values. The baseline scenario (VBS=0% and EPT=0%) and current intervention level (VBS=7.5% and EPT=27%) are marked in crosses, which shows an 8.1% relative reduction in women’s prevalence. To achieve a 30% relative reduction in women’s Ct prevalence, the combined intervention levels required are marked by the dashed contour line. For example, with a coverage of 30% male-screening and 40% partner treatment, the model predicts that the Ct prevalence in AA women will be reduced to 9.45%. AA, African American; Ct, Chlamydia trachomatis.